Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative docetaxel + cisplatin + capecitabine in adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus
2008-001849-26Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and capecitabine in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Safety and Efficacy. Started Jul 2008; status: terminated.
02
Drugs
docetaxelcisplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2008-001849-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001849-26.